PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

Pharmaceutical Technology

MAY 2, 2023

IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000. There is currently a rich and diverse IO pipeline that aims to address these unmet needs, with 703 IO products currently in clinical trials.

Immunization 52

Immunization Vaccines 52

pharmaphorum

DECEMBER 2, 2020

It almost hadn’t made it through clinical development, facing problems with ineffective chiral isomers and limited efficacy in animal testing, but showed such impact in human trials that it blew the competition away. Likewise, tanezumab, an anti-osteoarthritic, failed in trials. The post A history of Pfizer appeared first on.

Compounding 128

Compounding Vaccines Pharmaceutical Companies Pharmaceutical Companies 128

PharmaShots

MARCH 9, 2023

An elected member of Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI), she also serves fellow of the American Gastroenterological Association. For her efforts to promote inclusion, equity, and diversity, she was given the President's AwardTM by the National Diversity Council in 2021.

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40